ECTE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ECTE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. Echo Therapeutics's Operating Income for the three months ended in Sep. 2016 was $-1.81 Mil. Echo Therapeutics's Revenue for the three months ended in Sep. 2016 was $0.00 Mil. Therefore, Echo Therapeutics's Operating Margin % for the quarter that ended in Sep. 2016 was 0.00%.
The historical rank and industry rank for Echo Therapeutics's Operating Margin % or its related term are showing as below:
Echo Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Echo Therapeutics's Operating Income for the three months ended in Sep. 2016 was $-1.81 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2016 was $-6.26 Mil.
The historical data trend for Echo Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Echo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Operating Margin % | Get a 7-Day Free Trial | -1,846.76 | -300,800.00 | -70,160.71 | -21,614.04 | - |
Echo Therapeutics Quarterly Data | ||||||||||||||||||||
Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | |
Operating Margin % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Medical Devices subindustry, Echo Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Echo Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Echo Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Echo Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2015 is calculated as
Operating Margin % | = | Operating Income (A: Dec. 2015 ) | / | Revenue (A: Dec. 2015 ) |
= | -7.636 | / | 0 | |
= | % |
Echo Therapeutics's Operating Margin % for the quarter that ended in Sep. 2016 is calculated as
Operating Margin % | = | Operating Income (Q: Sep. 2016 ) | / | Revenue (Q: Sep. 2016 ) |
= | -1.814 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Echo Therapeutics (OTCPK:ECTE) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of Echo Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael M Goldberg | director | C/O MONTAUR CAPITAL PARTNERS, 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Uri Landesman | 10 percent owner | 230 PARK AVENUE, NEW YORK NY 10169 |
Platinum Partners Value Arbitrage Fund, Lp | 10 percent owner | 250 WEST 55TH STREET, 14TH FLOOR, NEW YORK NY 10019 |
Mark Nordlicht | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Platinum Management (ny) Llc | 10 percent owner | 250 WEST 55TH STREET, NEW YORK NY 10019 |
Platinum-montaur Life Sciences, Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Platinum Partners Liquid Opportunity Master Fund L.p. | 10 percent owner | 152 WEST 57 STREET, 4TH FLOOR, NEW YORK NY 10019 |
Platinum Liquid Opportunity Management (ny) Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Bernhardt Charles Thomas Iii | officer: Interim CFO | 23 BIRCH ROAD, MALVERN PA 19355 |
Vincent D Enright | director | ONE CORPORATE CENTER, RYE NY 10580 |
William Grieco | director | 830 CRESCENT CENTRE DRIVE, SUITE 610, FRANKLIN TN 37067 |
Platinum Long Term Growth Vii, Llc | 10 percent owner | 152 WEST 57TH STREET, 4TH FLOOR, NEW YORK NY 10019 |
Robert F Doman | director, officer: EXEC. CHAIRMAN AND INTERIM CEO | C/O DUSA PHARMACEUTICALS, INC., 25 UPTON DRIVE, WILMINGTON MA 01887 |
Patrick T Mooney | director, officer: CEO AND PRESIDENT | C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038 |
Christopher P. Schnittker | officer: CFO | 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540 |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.